Prostate-Specific Antigen Velocity And The Detection Of Gleason Score 7 To 10 Prostate Cancer

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Men's health
Article Date: 17 Feb 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

UroToday.com- Rapid prostate specific antigen velocity (PSAV) is associated with worse survival following local therapy for prostate cancer (CaP). Rapid PSAV prior to therapy is also associated with adverse pathologic features including higher Gleason score, seminal vesicle invasion, pelvic lymph node metastasis, time to PSA recurrence, CaP specific and all-cause mortality after surgery or radiotherapy. In this November 1, 2007 Cancer publication, Dr. Punglia and associates of Dr. Anthony D'Amico evaluated whether the PSAV during the 1.5 years before prostate biopsy was associated with CaP detection and grade the diagnosis in men with PSA levels >4ng/ml.

Between 1989 and 2003, 914 men with a PSA level >4ng/ml, clinical stage T1c, and at least 2 PSA measurements at 1 of 9 Center for Prostate Disease Research (CPDR) sites were included in the study cohort. Of these men, 541 men were diagnosed with CaP. Each of the participants had at least 2 pre-biopsy PSA levels at least 6 months apart and within 18 months of diagnosis. The PSAV was calculated by linear regression from these values. In the statistical analysis, three dependent outcomes were examined using multivariable regression; cancer versus no cancer, cancer with biopsy Gleason scores from 2 to 6 versus no cancer, and cancers with biopsy Gleason scores from 7 to 10 versus either Gleason scores <6 or no cancer. Covariates included a variety of continuous and categorical variables.

A total of 167 of the 541 men had Gleason score 7-10 CaP. An increasing PSA velocity was associated with Gleason score 7-10 disease versus Gleason score 2 to 6 or no cancer. This association was not found for men with Gleason score 2-6 CaP or for any CaP. Interestingly, PSA level was associated with the detection of any CaP and Gleason score <6 CaP but in the presence of PSAV, PSA no longer remained independently predictive for high-grade CaP. These data suggest that PSAV may be a predictor for the diagnosis of high-grade CaP.

Cancer. 110(9):1973-8, November 2007

Doi: 10.1002/cncr.23014

Reported by UroToday.com Contributing Editor Christopher P. Evans, M.D

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------